HomeTrialNCT02766543
🔬NCT02766543NAACTIVE NOT RECRUITING

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

Study Summary

A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.

Conditions
View on ClinicalTrials.gov ↗
Study Details
Enrollment150 participants
Primary Completion
Lead SponsorProfound Medical Inc.
Data Retrieved2026-04-11 04:24:51.229934+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.